Kiora Pharmaceuticals (KPRX) Competitors

$2.56 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$2.62 +0.06 (+2.34%)

As of 05/22/2026 06:44 PM Eastern

KPRX vs. TLPH, OKUR, XLO, IXHL, and ZYBT

Should you buy Kiora Pharmaceuticals stock or one of its competitors? MarketBeat compares Kiora Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kiora Pharmaceuticals include Talphera (TLPH), OnKure Therapeutics (OKUR), Xilio Therapeutics (XLO), Incannex Healthcare (IXHL), and Zhengye Biotechnology (ZYBT). These companies are all part of the "pharmaceutical products" industry.

How does Kiora Pharmaceuticals compare to Talphera?

Talphera (NASDAQ:TLPH) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Talphera had 3 more articles in the media than Kiora Pharmaceuticals. MarketBeat recorded 3 mentions for Talphera and 0 mentions for Kiora Pharmaceuticals. Kiora Pharmaceuticals' average media sentiment score of 0.00 beat Talphera's score of -0.19 indicating that Kiora Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Talphera	Neutral
Kiora Pharmaceuticals	Neutral

Talphera has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market. Comparatively, Kiora Pharmaceuticals has a beta of -0.48, meaning that its stock price is 148% less volatile than the broader market.

37.7% of Talphera shares are held by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are held by institutional investors. 3.5% of Talphera shares are held by company insiders. Comparatively, 0.1% of Kiora Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Talphera presently has a consensus target price of $3.00, suggesting a potential upside of 268.05%. Kiora Pharmaceuticals has a consensus target price of $10.00, suggesting a potential upside of 290.63%. Given Kiora Pharmaceuticals' higher possible upside, analysts plainly believe Kiora Pharmaceuticals is more favorable than Talphera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Talphera	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Kiora Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Kiora Pharmaceuticals has higher revenue and earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than Kiora Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Talphera	$30K	1,410.12	-$14.29M	-$0.31	N/A
Kiora Pharmaceuticals	$16.02M	0.71	-$10.84M	-$2.71	N/A

Kiora Pharmaceuticals' return on equity of -59.30% beat Talphera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Talphera	N/A	-92.98%	-53.22%
Kiora Pharmaceuticals	N/A	-59.30%	-41.23%

Summary

Kiora Pharmaceuticals beats Talphera on 8 of the 13 factors compared between the two stocks.

How does Kiora Pharmaceuticals compare to OnKure Therapeutics?

Kiora Pharmaceuticals (NASDAQ:KPRX) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends.

Kiora Pharmaceuticals has higher revenue and earnings than OnKure Therapeutics. OnKure Therapeutics is trading at a lower price-to-earnings ratio than Kiora Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiora Pharmaceuticals	$16.02M	0.71	-$10.84M	-$2.71	N/A
OnKure Therapeutics	N/A	N/A	-$59.52M	-$4.33	N/A

In the previous week, OnKure Therapeutics had 1 more articles in the media than Kiora Pharmaceuticals. MarketBeat recorded 1 mentions for OnKure Therapeutics and 0 mentions for Kiora Pharmaceuticals. Kiora Pharmaceuticals' average media sentiment score of 0.00 equaled OnKure Therapeutics'average media sentiment score.

Company	Overall Sentiment
Kiora Pharmaceuticals	Neutral
OnKure Therapeutics	Neutral

Kiora Pharmaceuticals has a beta of -0.48, suggesting that its stock price is 148% less volatile than the broader market. Comparatively, OnKure Therapeutics has a beta of 0.36, suggesting that its stock price is 64% less volatile than the broader market.

Kiora Pharmaceuticals currently has a consensus price target of $10.00, indicating a potential upside of 290.63%. OnKure Therapeutics has a consensus price target of $27.00, indicating a potential upside of 541.33%. Given OnKure Therapeutics' higher probable upside, analysts plainly believe OnKure Therapeutics is more favorable than Kiora Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiora Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
OnKure Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

77.0% of Kiora Pharmaceuticals shares are held by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are held by institutional investors. 0.1% of Kiora Pharmaceuticals shares are held by insiders. Comparatively, 2.3% of OnKure Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Kiora Pharmaceuticals' return on equity of -59.30% beat OnKure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiora Pharmaceuticals	N/A	-59.30%	-41.23%
OnKure Therapeutics	N/A	-61.02%	-55.99%

Summary

Kiora Pharmaceuticals beats OnKure Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Kiora Pharmaceuticals compare to Xilio Therapeutics?

Xilio Therapeutics (NASDAQ:XLO) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

Xilio Therapeutics has a beta of -0.16, suggesting that its stock price is 116% less volatile than the broader market. Comparatively, Kiora Pharmaceuticals has a beta of -0.48, suggesting that its stock price is 148% less volatile than the broader market.

Kiora Pharmaceuticals has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -58.52%. Kiora Pharmaceuticals' return on equity of -59.30% beat Xilio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xilio Therapeutics	-58.52%	-151.42%	-27.61%
Kiora Pharmaceuticals	N/A	-59.30%	-41.23%

Xilio Therapeutics currently has a consensus target price of $28.00, suggesting a potential upside of 239.39%. Kiora Pharmaceuticals has a consensus target price of $10.00, suggesting a potential upside of 290.63%. Given Kiora Pharmaceuticals' higher probable upside, analysts clearly believe Kiora Pharmaceuticals is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Kiora Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Kiora Pharmaceuticals has lower revenue, but higher earnings than Xilio Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Kiora Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xilio Therapeutics	$43.77M	1.13	-$35.04M	-$3.55	N/A
Kiora Pharmaceuticals	$16.02M	0.71	-$10.84M	-$2.71	N/A

In the previous week, Xilio Therapeutics' average media sentiment score of 1.00 beat Kiora Pharmaceuticals' score of 0.00 indicating that Xilio Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Xilio Therapeutics	Positive
Kiora Pharmaceuticals	Neutral

54.3% of Xilio Therapeutics shares are owned by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. 7.5% of Xilio Therapeutics shares are owned by company insiders. Comparatively, 0.1% of Kiora Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Xilio Therapeutics and Kiora Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Kiora Pharmaceuticals compare to Incannex Healthcare?

Incannex Healthcare (NASDAQ:IXHL) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, media sentiment, valuation, profitability and analyst recommendations.

Kiora Pharmaceuticals' return on equity of -59.30% beat Incannex Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incannex Healthcare	N/A	-81.01%	-76.11%
Kiora Pharmaceuticals	N/A	-59.30%	-41.23%

In the previous week, Incannex Healthcare had 1 more articles in the media than Kiora Pharmaceuticals. MarketBeat recorded 1 mentions for Incannex Healthcare and 0 mentions for Kiora Pharmaceuticals. Incannex Healthcare's average media sentiment score of 0.63 beat Kiora Pharmaceuticals' score of 0.00 indicating that Incannex Healthcare is being referred to more favorably in the media.

Company	Overall Sentiment
Incannex Healthcare	Positive
Kiora Pharmaceuticals	Neutral

Incannex Healthcare has a beta of 7.22, indicating that its stock price is 622% more volatile than the broader market. Comparatively, Kiora Pharmaceuticals has a beta of -0.48, indicating that its stock price is 148% less volatile than the broader market.

Kiora Pharmaceuticals has higher revenue and earnings than Incannex Healthcare. Incannex Healthcare is trading at a lower price-to-earnings ratio than Kiora Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incannex Healthcare	$90K	468.16	-$46.88M	-$1.55	N/A
Kiora Pharmaceuticals	$16.02M	0.71	-$10.84M	-$2.71	N/A

0.4% of Incannex Healthcare shares are owned by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. 1.3% of Incannex Healthcare shares are owned by company insiders. Comparatively, 0.1% of Kiora Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Kiora Pharmaceuticals has a consensus price target of $10.00, suggesting a potential upside of 290.63%. Given Kiora Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Kiora Pharmaceuticals is more favorable than Incannex Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Kiora Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Kiora Pharmaceuticals beats Incannex Healthcare on 9 of the 15 factors compared between the two stocks.

How does Kiora Pharmaceuticals compare to Zhengye Biotechnology?

Zhengye Biotechnology (NASDAQ:ZYBT) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

Zhengye Biotechnology has a beta of -2.47, meaning that its stock price is 347% less volatile than the broader market. Comparatively, Kiora Pharmaceuticals has a beta of -0.48, meaning that its stock price is 148% less volatile than the broader market.

77.0% of Kiora Pharmaceuticals shares are held by institutional investors. 0.1% of Kiora Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Zhengye Biotechnology's average media sentiment score of 0.00 equaled Kiora Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Zhengye Biotechnology	Neutral
Kiora Pharmaceuticals	Neutral

Kiora Pharmaceuticals has a consensus price target of $10.00, suggesting a potential upside of 290.63%. Given Kiora Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Kiora Pharmaceuticals is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Kiora Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Zhengye Biotechnology's return on equity of 0.00% beat Kiora Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zhengye Biotechnology	N/A	N/A	N/A
Kiora Pharmaceuticals	N/A	-59.30%	-41.23%

Zhengye Biotechnology has higher revenue and earnings than Kiora Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zhengye Biotechnology	$16.64M	2.47	-$9.98M	N/A	N/A
Kiora Pharmaceuticals	$16.02M	0.71	-$10.84M	-$2.71	N/A

Summary

Kiora Pharmaceuticals beats Zhengye Biotechnology on 6 of the 11 factors compared between the two stocks.

Get Kiora Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KPRX vs. The Competition

Export

Metric	Kiora Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$11.35M	$3.04B	$6.46B	$12.34B
Dividend Yield	N/A	1.97%	2.76%	5.28%
P/E Ratio	-0.94	17.79	21.22	25.66
Price / Sales	0.71	336.21	562.28	86.31
Price / Cash	N/A	57.74	43.49	56.67
Price / Book	0.82	5.86	10.31	7.14
Net Income	-$10.84M	$74.99M	$3.57B	$335.98M
7 Day Performance	1.59%	3.11%	6.43%	4.15%
1 Month Performance	8.94%	-3.05%	3.57%	2.54%
1 Year Performance	-16.34%	34.38%	34.07%	35.06%

Kiora Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KPRX Kiora Pharmaceuticals	1.8718 of 5 stars	$2.56 flat	$10.00 +290.6%	-16.3%	$11.35M	$16.02M	N/A	10	Gap Up
TLPH Talphera	3.2377 of 5 stars	$0.90 +5.1%	$3.00 +232.9%	+61.1%	$46.78M	$28K	N/A	19
OKUR OnKure Therapeutics	2.5936 of 5 stars	$3.40 +0.3%	$27.00 +694.1%	+95.8%	$46.48M	N/A	N/A	N/A
XLO Xilio Therapeutics	3.3073 of 5 stars	$7.76 +0.4%	$28.00 +260.8%	-33.3%	$46.43M	$43.77M	N/A	70	Positive News
IXHL Incannex Healthcare	0.909 of 5 stars	$3.85 -1.3%	N/A	-46.1%	$45.94M	N/A	N/A	3	Analyst Upgrade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KPRX) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kiora Pharmaceuticals (KPRX) Competitors

KPRX vs. TLPH, OKUR, XLO, IXHL, and ZYBT

How does Kiora Pharmaceuticals compare to Talphera?

Summary

How does Kiora Pharmaceuticals compare to OnKure Therapeutics?

Summary

How does Kiora Pharmaceuticals compare to Xilio Therapeutics?

Summary

How does Kiora Pharmaceuticals compare to Incannex Healthcare?

Summary

How does Kiora Pharmaceuticals compare to Zhengye Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KPRX vs. The Competition

Kiora Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kiora Pharmaceuticals (KPRX) Competitors

KPRX vs. TLPH, OKUR, XLO, IXHL, and ZYBT

How does Kiora Pharmaceuticals compare to Talphera?

Does the media prefer TLPH or KPRX?

Which has more risk & volatility, TLPH or KPRX?

Do insiders and institutionals hold more shares of TLPH or KPRX?

Do analysts prefer TLPH or KPRX?

Which has stronger earnings and valuation, TLPH or KPRX?

Is TLPH or KPRX more profitable?

Summary

How does Kiora Pharmaceuticals compare to OnKure Therapeutics?

Which has stronger valuation and earnings, KPRX or OKUR?

Does the media favor KPRX or OKUR?

Which has more volatility & risk, KPRX or OKUR?

Do analysts prefer KPRX or OKUR?

Do insiders and institutionals believe in KPRX or OKUR?

Is KPRX or OKUR more profitable?

Summary

How does Kiora Pharmaceuticals compare to Xilio Therapeutics?

Which has more risk and volatility, XLO or KPRX?

Is XLO or KPRX more profitable?

Do analysts recommend XLO or KPRX?

Which has preferable valuation and earnings, XLO or KPRX?

Does the media prefer XLO or KPRX?

Do institutionals and insiders have more ownership in XLO or KPRX?

Summary

How does Kiora Pharmaceuticals compare to Incannex Healthcare?

Is IXHL or KPRX more profitable?

Does the media refer more to IXHL or KPRX?

Which has more risk and volatility, IXHL or KPRX?

Which has preferable earnings and valuation, IXHL or KPRX?

Do insiders and institutionals hold more shares of IXHL or KPRX?

Do analysts prefer IXHL or KPRX?

Summary

How does Kiora Pharmaceuticals compare to Zhengye Biotechnology?

Which has more volatility & risk, ZYBT or KPRX?

Do insiders and institutionals have more ownership in ZYBT or KPRX?

Does the media favor ZYBT or KPRX?

Do analysts prefer ZYBT or KPRX?

Is ZYBT or KPRX more profitable?

Which has stronger earnings & valuation, ZYBT or KPRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KPRX vs. The Competition

Kiora Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools